Baseline ECG and Cardiovascular Outcomes in People With HIV: Insights From REPRIEVE.

ABSTRACT:

Background

With antiretroviral therapy, people with HIV (PWH) have an increased burden of cardiovascular disease. The REPRIEVE (Randomized Trial to Prevent Vascular Events in HIV) trial demonstrated that pitavastatin reduces major adverse cardiovascular events (MACEs) among PWH at low to moderate traditional atherosclerotic risk. Electrocardiographic abnormalities are common in PWH, but little is known about their association with MACEs. We sought to examine whether baseline electrocardiographic abnormalities are associated with increased MACE risk among a global primary cardiovascular disease prevention cohort of PWH in REPRIEVE.

Methods

In this observational analysis, entry electrocardiographic abnormalities were adjudicated and classified as major or minor abnormalities.

SUBMITTER: Awwad A 

PROVIDER: S-EPMC12826942 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature